about
Phenotype difference between familial and sporadic ankylosing spondylitis in Korean patientsFour-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study.Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea.Modeling quality of life in patients with rheumatic diseases: the role of pain catastrophizing, fear-avoidance beliefs, physical disability, and depression.Nonthrombotic proliferative vasculopathy associated with antiphospholipid antibodies: A case report and literature review.Erratum to "Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients"Periodontal inflamed surface area as a novel numerical variable describing periodontal conditions.Elderly Patients Exhibit Stronger Inflammatory Responses during Gout Attacks.Treponema denticola enolase contributes to the production of antibodies against ENO1 but not to the progression of periodontitisInfliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm studyCirculating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid ArthritisTreat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in KoreaPeriodontal pathogens and the association between periodontitis and rheumatoid arthritis in Korean adultsRaynaud's phenomenon and anti-nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositisSerum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue diseaseLong-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised,Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: A case-control study in South KoreaA network analysis of the Brief Illness Perception Questionnaire in patients with rheumatic diseases and human immunodeficiency virus infectionLBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritisGlycoprotein 96 polymorphisms are associated with the risk of systemic lupus erythematosus: A case-control studyEfficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexatePerformance of the 2015 American College of Rheumatology/European League against Rheumatism Classification Criteria for Gout in Korean Patients with Acute ArthritisPotential clinical utility of a novel optical tomographic imaging for the quantitative assessment of hand rheumatoid arthritisA 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing SpondylitisCare for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLARTocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study
P50
Q33749170-8633946F-4990-4160-9C74-1568F3B46CAAQ34029936-6A6079FD-253C-43CF-BE9F-67B428E96F89Q36656406-9CD10852-26AA-4D31-84BA-215A43FC163BQ37542648-68691391-A034-4AC8-95AE-A01240B1DF75Q37583028-BE034280-1590-4E21-A9C4-E699444B78D4Q38908843-60E6E716-6967-4BA5-8E87-8BEA88009036Q38930485-C2F339CB-4734-47CD-8045-20F8BB430821Q42354195-3BCF1E67-D6B0-4BAF-BE66-E3771C7020BFQ47148743-AFC811D1-0F31-4A57-9433-8566E62DF3E6Q47161863-F340AD66-5829-408B-8F44-D80662D739EFQ58773688-FD0960BC-A978-48EE-9DAF-F0DD7F071DEDQ59130566-ADE25248-105D-4218-BA3D-1A361410E5B8Q59806580-5A7CE90E-8C26-4503-83B2-8EDD645B7EF6Q60301158-48B7DD57-1F7B-4862-B730-E67473850381Q60928282-15A1C2C3-39E1-406C-ACFD-465BFE0DC19FQ64119773-A826CF03-9C0E-460F-86BF-4E8459727184Q64245593-77FB0468-6D90-4258-ABD5-2E0DB5C2B010Q64271017-CD33C7EA-7F15-4C47-BBA0-ECF749EAA169Q90157205-9B81982A-D9D0-477B-BB4D-D9A38B03BBD6Q91127052-72892325-E890-45AB-9BF9-EDB20C12F869Q91694109-0DE0D079-6436-4A37-8F5F-5B5EA0AB0CC3Q92297771-AE5D8B3F-705D-4713-8B44-F26EC6FA5D19Q92301972-3BCC218A-5ED7-4174-BE24-41BCC19215E9Q92578803-8A92324D-B878-4711-BCC5-ACA3EE73B063Q92762814-0DAF622F-8D7A-4737-9A43-A5F6693FB66AQ93202421-04AA0D7C-4CDE-4DB8-ADAA-DC84BACC153CQ95938148-9295F0D7-9C18-46D8-8B0D-F25369E9BEECQ96167225-E0D33DD1-C00B-464B-92DA-3BC5BAF1535E
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-5384-3437
@en
name
Yeong Wook Song
@ast
Yeong Wook Song
@en
Yeong Wook Song
@es
Yeong Wook Song
@nl
type
label
Yeong Wook Song
@ast
Yeong Wook Song
@en
Yeong Wook Song
@es
Yeong Wook Song
@nl
prefLabel
Yeong Wook Song
@ast
Yeong Wook Song
@en
Yeong Wook Song
@es
Yeong Wook Song
@nl
P106
P31
P496
0000-0002-5384-3437